Zepbound Geriatric (65+) Caregiver Administration Guidance

What FDA Labeling Says About Zepbound in Older Adults

Eli Lilly's FDA-approved prescribing information for tirzepatide states that no dose adjustment is required based on age alone, but it acknowledges that older patients were enrolled in smaller numbers across the SURMOUNT trials and may carry more comorbidities that affect tolerability. [1] The label specifies starting at 2.5 mg once weekly and increasing by 2.5 mg increments no sooner than every four weeks, a schedule that applies to patients of all ages. [1]

Caregivers need to understand that "no dose adjustment required" does not mean "no extra caution required." Older adults are more likely to experience orthostatic hypotension, sarcopenia-related muscle loss, and inadequate caloric intake, all of which can be worsened by the nausea and anorexia that tirzepatide produces during dose escalation.

Why the Geriatric Population Was Under-Represented in SURMOUNT Trials

SURMOUNT-1 enrolled 2,539 participants with a mean age of 44.9 years; adults aged 65 or older made up roughly 15% of the trial population. [2] The lower enrollment of older adults means that adverse event rates specific to that cohort carry wider confidence intervals than those seen in the overall trial population.

SURMOUNT-4 specifically studied the effect of continuing versus stopping tirzepatide after initial weight loss and found that discontinuation led to substantial weight regain, a consideration for caregivers who may be tempted to pause injections during periods of illness in an older adult. [3]

Regulatory Classification and Approval Scope

The FDA approved Zepbound in May 2024 under NDA 217806 for adults with a BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea. [1] Caregivers should confirm that the older adult in their care meets this criterion before assuming the prescription is appropriate.

Pharmacology Relevant to Caregiver Decision-Making

Tirzepatide is a single molecule that activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. [4]

In older adults, slowed gastric emptying can interact with common medications. Drugs with narrow therapeutic windows, such as levothyroxine, warfarin, and digoxin, may have altered absorption when gastric transit time changes. The FDA label advises monitoring patients on oral medications that depend on threshold concentrations when initiating tirzepatide. [1]

Renal and Hepatic Considerations in Adults 65+

The tirzepatide prescribing information reports that mild, moderate, or severe renal impairment did not alter the pharmacokinetics of tirzepatide to a clinically meaningful degree in dedicated renal impairment studies. [1] However, dehydration secondary to vomiting or diarrhea can cause acute kidney injury in older adults with borderline renal function, making hydration monitoring a caregiver priority.

Hepatic impairment studies (mild, moderate, and severe) also showed no clinically relevant effect on tirzepatide exposure. [1] Still, caregivers of patients with cirrhosis should confirm the prescribing physician has reviewed baseline liver function.

Interaction with Insulin and Sulfonylureas

Older adults with type 2 diabetes who are also taking insulin or a sulfonylurea face a measurable hypoglycemia risk when tirzepatide is added to their regimen. In SURPASS-5, patients on insulin glargine plus tirzepatide experienced hypoglycemia at higher rates than those on insulin alone. [5] Caregivers should know the signs of hypoglycemia (shakiness, confusion, cold sweat, pale skin) and keep a fast-acting glucose source accessible at all times.

Step-by-Step Caregiver Injection Technique

The Zepbound autoinjector pen is designed for self-administration, but caregivers of older adults with arthritis, visual impairment, or cognitive decline may need to perform the injection. The process below follows the instructions for use approved by the FDA. [1]

Preparing the Injection

1. Remove the pen from the refrigerator 30 minutes before injection to allow it to reach room temperature. Cold solution increases injection-site discomfort.
2. Wash hands thoroughly with soap and water for at least 20 seconds.
3. Inspect the pen window. The solution should be clear to slightly yellow and free of particles. Do not use a pen that appears cloudy, discolored, or contains visible particulates. [1]
4. Check the expiration date printed on the pen label. Expired pens should be disposed of in a sharps container, not used.

Selecting and Preparing the Injection Site

Rotate among three body regions: the abdomen (at least two inches away from the navel), the upper arm (outer area), and the thigh (front or outer surface). [1] In older adults with reduced subcutaneous fat, the abdomen is generally preferred because it has more consistent tissue depth.

Wipe the selected site with an alcohol swab and allow it to air-dry completely. Wet skin can carry the alcohol into the injection track, causing a stinging sensation and potentially introducing contaminants.

Performing the Injection

1. Remove the base cap from the pen. Do not remove the needle cap yet if a delay is needed.
2. Remove the needle cap just before injection.
3. Hold the pen at a 90-degree angle to the skin. For older adults with very low body fat, a skin fold may be pinched with the non-dominant hand before pressing the pen against the skin.
4. Press the pen firmly against the skin until you hear a click. Hold the pen in place for 10 seconds to ensure the full dose is delivered. [1]
5. Lift the pen straight away from the skin. The needle retracts automatically.
6. If a small amount of blood or medication appears at the injection site, apply gentle pressure with a clean gauze pad. Do not rub.
7. Dispose of the used pen immediately in an FDA-cleared sharps disposal container. [6]

Monitoring Older Adults for Adverse Effects

The most common adverse effects of tirzepatide across the SURMOUNT trials were gastrointestinal: nausea (18% to 24% for doses above 5 mg), diarrhea (17% to 22%), vomiting (8% to 13%), and constipation (6% to 11%). [2] These rates were measured in a mostly middle-aged trial population; caregivers of adults 65+ should treat these figures as floor estimates rather than upper bounds.

Nausea, Vomiting, and Dehydration Risk

Nausea is most intense during the first four to eight weeks after each dose escalation. Caregivers should offer small, bland meals every three to four hours rather than three large meals per day. The American Diabetes Association 2024 Standards of Care recommend starting GLP-1 and dual agonist therapy at the lowest dose and increasing slowly specifically to minimize gastrointestinal side effects. [7]

Persistent vomiting lasting more than 24 hours in an adult aged 65 or older is a red flag. Dehydration develops faster in older adults because total body water declines with age. A 2023 analysis in JAMA Internal Medicine found that older adults taking GLP-1 receptor agonists had a statistically significant higher rate of serious gastrointestinal events requiring hospitalization compared with adults taking other anti-obesity medications. [8]

Caregivers should monitor for signs of dehydration: dry mouth, dark urine, dizziness when standing, and confusion. Any of these signs combined with inability to keep fluids down warrants a same-day call to the prescriber or urgent care evaluation.

Fall Risk and Orthostatic Hypotension

Dizziness affects roughly 5% to 8% of tirzepatide-treated patients in clinical trials. [2] In older adults, even mild dizziness substantially raises fall risk. The Centers for Disease Control and Prevention estimates that falls are the leading cause of fatal and non-fatal injuries in adults aged 65 and older in the United States. [9]

Caregivers should advise the older adult to rise slowly from seated or lying positions, especially in the first 12 to 24 hours after each weekly injection. Grab bars in bathrooms and removal of loose rugs are practical home modifications worth considering when a patient first starts tirzepatide or after each dose increase.

Muscle Mass Preservation

Weight loss from GLP-1 and dual GIP/GLP-1 agonists includes both fat mass and lean mass. A 2023 randomized study published in Diabetes Care found that approximately 25% to 39% of weight lost on semaglutide (a structurally related GLP-1 agonist) was lean tissue rather than fat in older adults. [10] There are no tirzepatide-specific geriatric body composition trials published as of mid-2025, but the mechanism suggests a similar pattern is possible.

Caregivers should encourage resistance exercise (two to three sessions per week) and protein intake of at least 1.0 to 1.2 grams per kilogram of body weight per day to offset lean mass loss. The prescriber should be informed if the older adult stops eating sufficient protein or avoids all physical activity.

Storage, Handling, and Travel Considerations

The FDA-approved prescribing information specifies that Zepbound pens must be refrigerated at 36°F to 46°F (2°C to 8°C) until use. [1] If removed from refrigeration, pens may be stored at room temperature up to 86°F (30°C) for a maximum of 21 days. After 21 days at room temperature, unused pens must be discarded.

Refrigerator Organization for Multi-Medication Households

Many older adults manage five or more daily medications. A 2019 study in the Annals of Internal Medicine found that adults 65 and older take a mean of 4.5 prescription medications, with refrigerated biologics adding an organizational burden. [11] Caregivers should store Zepbound pens in a labeled bin on a dedicated refrigerator shelf, away from food items that could disguise leakage or temperature violations.

Do not freeze Zepbound pens. Freezing damages the autoinjector mechanism and may alter the drug formulation. If a pen is accidentally frozen, discard it and contact the pharmacy for a replacement. [1]

Traveling with Tirzepatide

For air travel, carry pens in a TSA-compliant insulated medication pouch in carry-on luggage, never in checked baggage where cargo hold temperatures may drop below freezing. The FDA advises patients and caregivers to bring a letter from the prescriber explaining the need for injectable medications and sharps supplies when traveling by air. [6] For trips longer than 21 days, ensure the destination pharmacy or mail-order service can supply additional pens.

Dose Escalation Schedule and When to Hold a Dose

The standard escalation for Zepbound follows a fixed schedule:

| Week Range | Dose | |---|---| | Weeks 1 to 4 | 2.5 mg once weekly | | Weeks 5 to 8 | 5 mg once weekly | | Weeks 9 to 12 | 7.5 mg once weekly | | Weeks 13 to 16 | 10 mg once weekly | | Weeks 17 to 20 | 12.5 mg once weekly | | Week 21 onward | 15 mg once weekly (if tolerated) |

Many prescribers extend each dose level by an additional four weeks in older adults or those with persistent gastrointestinal side effects. Caregivers should never increase the dose faster than prescribed, even if the patient feels the current dose is well tolerated.

When to Delay a Scheduled Injection

The prescribing information states that if a dose is missed and the next scheduled dose is more than four days away, the missed dose may be administered. If the next scheduled dose is within four days, skip the missed dose and resume the regular schedule. [1] Do not double-dose.

Caregivers should hold the injection and contact the prescriber if the older adult is actively vomiting on the day the dose is due, is acutely ill with fever above 101°F, or has been instructed to fast for a scheduled surgical or procedural procedure. Post-operative resumption timing should be confirmed with the surgical team, as the gastric emptying effect of tirzepatide has implications for anesthesia safety. The American Society of Anesthesiologists issued guidance in 2023 recommending that GLP-1 receptor agonists be held for at least one weekly dosing interval before elective procedures requiring general anesthesia due to aspiration risk. [12]

Recognizing Signs That Dose Escalation Should Pause

Caregivers should communicate the following observations to the prescriber before the next scheduled dose increase:

• Ongoing nausea rated 4 or above on a 10-point scale despite dietary adjustments
• More than two episodes of vomiting in a single week
• Unintentional weight loss exceeding 2 lbs per week over three consecutive weeks (may indicate inadequate caloric intake)
• New or worsening kidney-related symptoms such as decreased urine output
• Any new abdominal pain radiating to the back, which may indicate pancreatitis, a rare but serious adverse event listed in the FDA black box section of the label [1]

Pancreatitis, Thyroid C-Cell Tumor Risk, and Other Serious Warnings

The FDA label carries a boxed warning for tirzepatide noting that in rodent studies, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. [1] The relevance to humans is currently unknown, but tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Caregivers should confirm this history has been reviewed by the prescriber.

Acute pancreatitis has been reported in patients taking GLP-1 class medications. A 2022 meta-analysis in Diabetes, Obesity and Metabolism found no statistically significant increase in acute pancreatitis rates for GLP-1 receptor agonists versus comparators across 60 randomized trials, though individual case reports continue to appear. [13] Any sudden severe abdominal pain should be treated as a medical emergency.

Gallbladder Disease

Significant weight loss from any cause increases the risk of gallstone formation and cholecystitis. The tirzepatide label reports that cholelithiasis occurred in 0.6% of patients on tirzepatide versus 0.2% of patients on placebo. [1] Caregivers of older adults who report right upper quadrant pain, especially after meals, should not assume this is a gastrointestinal side effect of tirzepatide without ruling out gallbladder pathology through appropriate imaging.

Communication Framework Between Caregiver and Prescriber

Caregivers often serve as the primary channel of clinical information when an older adult has cognitive impairment or communication difficulties. A structured weekly check-in approach helps avoid both under-reporting and over-reporting.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Shared decision-making between the patient, caregiver, and prescribing clinician is essential to optimizing outcomes in older adults receiving anti-obesity pharmacotherapy, given the higher baseline rate of polypharmacy and functional limitations in this population." [14]

Caregivers should keep a simple weekly log noting: injection date and time, injection site used, any gastrointestinal symptoms and their severity (1 to 10 scale), weight (if measured), and any falls or near-falls. Bringing this log to every follow-up visit gives the prescriber concrete data rather than general impressions.

How to Reach the Prescriber Between Visits

Most telehealth platforms, including HealthRX, provide a secure messaging portal for between-visit questions. Caregivers should use this channel for non-urgent concerns and reserve phone calls for situations requiring same-day guidance, such as inability to tolerate fluids for more than 12 hours, new neurological symptoms, or suspected injection-site infection (redness, warmth, swelling, or pus at the injection site persisting beyond 48 hours).